Trials / Completed
CompletedNCT02581020
The Durability of Response and Persistence of Resistance to AbbVie's 2 Direct-acting Antiviral Agent (2D) Therapy in Japanese Subjects
A Follow-up Study to Assess the Durability of Response and Persistence of Resistance to AbbVie's 2 Direct-acting Antiviral Agent (2D) Therapy in Japanese Subjects Who Participated in Phase 2 or 3 Clinical Studies for the Treatment of Chronic Hepatitis C Virus (HCV) Infection
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 344 (actual)
- Sponsor
- AbbVie · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This study seeks to assess the durability of response and persistence of resistance to ombitasvir/ paritaprevir/ritonavir in Japanese participants who enrolled in a Phase 2 or 3 clinical study with these agents for the treatment of chronic hepatitis C.
Conditions
Timeline
- Start date
- 2016-01-14
- Primary completion
- 2020-12-08
- Completion
- 2020-12-08
- First posted
- 2015-10-20
- Last updated
- 2021-12-08
Locations
53 sites across 1 country: Japan
Source: ClinicalTrials.gov record NCT02581020. Inclusion in this directory is not an endorsement.